Page last updated: 2024-12-05

fleroxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fleroxacin is a synthetic, broad-spectrum fluoroquinolone antibiotic. It has been studied for its potential in treating various bacterial infections, including urinary tract infections, respiratory tract infections, and skin infections. Its mechanism of action involves inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication and repair. Fleroxacin is known for its high oral bioavailability and good tissue penetration. However, due to the emergence of bacterial resistance and concerns about potential adverse effects, its use has become less common in some regions. Research on fleroxacin continues to investigate its potential for specific applications, including the treatment of multi-drug resistant infections.'

Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3357
CHEMBL ID6273
CHEBI ID31810
SCHEMBL ID48145
MeSH IDM0025289

Synonyms (90)

Synonym
fleroxacino [spanish]
fleroxacine [french]
ro 23-6240/000
brn 4300996
am 833
3-quinolinecarboxylic acid, 1,4-dihydro-6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-
fleroxacinum [latin]
3-quinolinecarboxylic acid, 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-
ccris 3972
ro 23-6240
AB00640001-02
ro-236240
am-833
quinodis
megalosin
megalocin
ro-23-6240/000
megalone
79660-53-0
6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid
79660-72-3
fleroxacin
smr000466302
MLS000759401
DB04576
fleroxicin
fleroxacin (jan/usan/inn)
megalocin (tn)
flrx
D01716
megalone (tn)
NCGC00167558-01
HMS2090I08
F0646 ,
ro-236240000
CHEMBL6273
chebi:31810 ,
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
A839732
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid;fleroxacin
fleroxacin [usan:inn:ban:jan]
fleroxacine
n804ldh51k ,
unii-n804ldh51k
tox21_112553
cas-79660-72-3
dtxcid9026714
dtxsid1046714 ,
fleroxacino
fleroxacinum
FT-0630874
AKOS015907011
S2469
CCG-221125
HY-B0414
SCHEMBL48145
MLS006010715
tox21_112553_1
NCGC00167558-02
KS-5124
fleroxacin [jan]
fleroxacin [who-dd]
fleroxacin [mi]
fleroxacin [usan]
fleroxacin [inn]
fleroxacin [mart.]
AB00640001-03
mfcd00864880
6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid-
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
XBJBPGROQZJDOJ-UHFFFAOYSA-N
zinc03786299
AB00640001_04
SR-01000759379-2
sr-01000759379
SR-01000759379-3
fleroxacin, vetranal(tm), analytical standard
HMS3715B11
rkl10075
bdbm50247892
BCP28939
Q3746573
fleroxacin (quinodis)
fleroxacin,(s)
ro 23-6240;am-833
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylicacid
gtpl12476
SY057457
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

Research Excerpts

Overview

Fleroxacin (FLRX) is a new member of the class of fluoroquinolones. Its effects on human serum albumin (HSA) and the mechanism of action are poorly understood, Especially, the secondary structural alterations of HSA induced by FLRX and the inner filter effect.

ExcerptReferenceRelevance
"Fleroxacin (FLE) is a widely used fluoroquinolones to cure urinary tract infections and respiratory disease, which has been frequently detected in the aquatic environment. "( Comparison of fleroxacin oxidation by chlorine and chlorine dioxide: Kinetics, mechanism and halogenated DBPs formation.
Chen, F; Dong, F; He, G; Hu, J; Li, J; Li, Y; Zhang, T, 2022
)
2.52
"Fleroxacin (FLRX) is a new member of the class of fluoroquinolones, its effects on human serum albumin (HSA) and the mechanism of action are poorly understood, Especially, the secondary structural alterations of HSA induced by FLRX and the inner filter effect, which resulted in a spurious decrease in the observed fluorescence intensity and affected the binding parameters calculated from it are not considered. "( Spectroscopic and Molecular Modeling Studies on Binding of Fleroxacin with Human Serum Albumin.
Dong, CY; Liu, Y; Xu, J; Zhou, SS, 2017
)
2.14
"Fleroxacin is a new broad-spectrum quinolone which can be given by the oral route. "( Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.
Cerruti, F; Herrmann, M; Hirschel, B; Leemann, T; Lew, DP; Portmann, R; Schrenzel, J; Weidekamm, E, 1994
)
2
"Fleroxacin is a safe and effective antibiotic for sequential intravenous and oral treatment of acute pyelonephritis and complicated UTIs."( A sequential study of intravenous and oral fleroxacin in the treatment of complicated urinary tract infection.
Amarshi, N; Craft, RB; Gelfand, MS; Grogan, J; Simmons, BP, 1993
)
1.27
"Fleroxacin is an acceptable alternative to existing treatment regimens for chancroid in men."( Fleroxacin in the treatment of chancroid: an open study in men seropositive or seronegative for the human immunodeficiency virus type 1.
Agoki, E; Malisa, W; Ndinya-Achola, JO; Plourde, PJ; Plummer, FA; Ronald, AR; Tyndall, MW, 1993
)
2.45
"Fleroxacin is a new oral and intravenous trifluorinated 4-quinolone, which acts by inhibiting the essential bacterial enzyme DNA gyrase. "( Fleroxacin overview.
Naber, KG, 1996
)
3.18
"Fleroxacin is a new fluoroquinolone with established potent antimicrobial and pharmacokinetic properties, and the aim of this study was to determine its rate of penetration into human lung, muscle, and fat tissues. "( Penetration of fleroxacin into human lung, muscle, and fat tissue.
Cakmakci, M; Geroulanos, S; Gossweiler, L; Schilling, J; Schlumpf, R, 1992
)
2.08
"Fleroxacin is a new member of the class of fluoroquinolones. "( Fleroxacin clinical pharmacokinetics.
Frey, FJ; Kim, DK; Stuck, AE, 1992
)
3.17
"Fleroxacin is an effective antimicrobial agent against most staphylococci."( Susceptibility of Staphylococcus species and subspecies to fleroxacin.
Bannerman, TL; Kloos, WE; Wadiak, DL, 1991
)
1.25
"Fleroxacin is a new fluoroquinolone with a broad antibacterial spectrum and a serum half-life of about 8-12 h. "( In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
Grobecker, H; Kees, F; Metz, R; Naber, KG; Schumacher, H; Sörgel, F, 1988
)
2.04
"Fleroxacin is a newly developed quinolone derivative with marked antimicrobial activity. "( Therapeutic effect of fleroxacin against experimental pneumonia in mice.
Niki, Y; Soejima, R; Tasaka, Y; Umeki, S; Watanabe, M, 1988
)
2.03
"Fleroxacin is a new synthetic fluorinated quinolone antimicrobial agent. "( In-vitro activity of fleroxacin.
Breyer, S; Georgopoulos, A; Georgopoulos, M; Graninger, W; Mailer, H, 1988
)
2.04
"Fleroxacin is a potent quinolone with in-vitro activity against a variety of resistant bacterial species."( In-vitro activity of fleroxacin against urinary tract and genital tract pathogens.
Dubois, J; Fontaine, V, 1988
)
1.32

Effects

Fleroxacin has a relatively long elimination half-life, which allows once-daily administration. It appears to have less propensity for interactions with other medications in comparison to many other fluoroquinolones.

ExcerptReferenceRelevance
"Fleroxacin has a relatively long elimination half-life, which allows once-daily administration, and it appears to have less propensity for interactions with other medications in comparison to many other fluoroquinolones."( Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
Balfour, JA; Peters, DH; Todd, PA, 1995
)
2.46
"Fleroxacin has a synergistic effect with ketoconazole (KETO), but this is not observed with itraconazole (ITRA) or fluconazole (FLU)."( In vitro and in vivo activity of antifungal agents in combination with fleroxacin, a new quinolone.
Polak, A, 1990
)
1.23
"Fleroxacin has a relatively long elimination half-life, which allows once-daily administration, and it appears to have less propensity for interactions with other medications in comparison to many other fluoroquinolones."( Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
Balfour, JA; Peters, DH; Todd, PA, 1995
)
2.46
"Fleroxacin has a synergistic effect with ketoconazole (KETO), but this is not observed with itraconazole (ITRA) or fluconazole (FLU)."( In vitro and in vivo activity of antifungal agents in combination with fleroxacin, a new quinolone.
Polak, A, 1990
)
1.23

Treatment

Fleroxacin was used to treat patients with phototoxicity and treatment-limiting adverse events.

ExcerptReferenceRelevance
"More fleroxacin-treated patients experienced phototoxicity and treatment-limiting adverse events."( Fleroxacin 400 mg once daily versus ofloxacin 400 mg twice daily in skin and soft tissue infections.
Barker, M; Drehobl, M; Koenig, L; Maladorno, D; St Clair, P,
)
2.03
"Fleroxacin treatments were continued until sacrifice."( Effect of fleroxacin on mouse bladder carcinogenesis with N-butyl-N- (4-hydroxybutyl) nitrosamine.
Ebisuno, S; Inagaki, T; Kohjimoto, Y; Nishihata, M; Nishikawa, T; Ohkawa, T; Watanabe, T, 1999
)
1.43

Toxicity

The overall rate of adverse reactions for patients treated with oral fleroxacin was 20% for those given a daily dose of 400 mg. Adverse events, particularly slight neuropsychiatric reactions (headache, insomnia) were more frequent in the flerOxacin-treated groups.

ExcerptReferenceRelevance
" Clinical adverse events related to the trial medication were reported by 40 (21%) of 189 patients in the fleroxacin group and by 16 (17%) of 95 patients in the AMX/CP group."( Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections.
Tassler, H, 1993
)
0.77
" The overall rate of adverse reactions for patients treated with oral fleroxacin was 20% for those given 200 mg daily and 20% for those given a daily dose of 400 mg."( Safety of fleroxacin in clinical trials.
Geddes, AM, 1993
)
0.92

Pharmacokinetics

Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g. h/liter) Fleroxacins levels in embryonic tissues were similar to maternal plasma levels, and there was a correlation between exposure and embryolethal doses for all fluoroquinolones.

ExcerptReferenceRelevance
"3, as predicted from the elimination half-life of 10 to 12h."( Fleroxacin clinical pharmacokinetics.
Frey, FJ; Kim, DK; Stuck, AE, 1992
)
1.73
"Although composite data from separate subjects can be used to generate single-subject estimates, intersubject variation precludes rigorous ocular pharmacokinetic analysis."( Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits.
Madu, A; Madu, CN; Mathisson, K; Mayers, M; Miller, MH; Rush, D; Samathanam, G, 1992
)
1.73
"6 mg/L, time to Cmax (tmax) was about 3h, elimination half-life (t1/2) was 16 +/- 1h and the percentage of unchanged fleroxacin excreted in urine was 39 +/- 3% of the dose."( Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Devillers, A; Fillastre, JP; Singlas, E; Taburet, AM; Thomare, P; Veyssier, P, 1990
)
0.84
"The pharmacokinetic properties of the new fluoroquinolones are characterized by a high volume of distribution, long biological half-life, low serum protein binding, elimination by renal and extrarenal mechanisms with high total and renal clearances, limited biotransformation and moderate to excellent bioavailability after oral administration."( Quinolone pharmacokinetics and metabolism.
Boeckk, M; Borner, K; Deppermann, N; Höffken, G; Koeppe, P; Lode, H, 1990
)
0.28
" For the other new quinolones, a decrease in glomerular filtration rate below 20-30 ml/min induces an increase in terminal half-life and a decrease in plasma and renal clearance, related to the degree of renal impairment."( Pharmacokinetics of quinolones in renal insufficiency.
Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990
)
0.28
" The extent to which Ro 23-9424 acts in vivo as a true dual-action cephalosporin, or acts as a combination of active metabolites, is therefore a function of its pharmacokinetic properties."( Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.
Chan, KK; Christenson, JG; Cleeland, R; Dix-Holzknecht, B; Farrish, HH; Patel, IH; Specian, A, 1990
)
0.28
" The volume of distribution, systemic availability, and peak concentration after the administration of oral fleroxacin were independent of the glomerular filtration rate."( Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
Brandt, R; Frey, FJ; Heizmann, P; Stuck, AE; Weidekamm, E, 1989
)
0.74
" The elimination half-life in serum was 11."( Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.
Ashby, J; Griggs, DJ; Kirkpatrick, B; Wise, R, 1987
)
0.27
" Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e."( Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
Dell, D; Lücker, PW; Partos, C; Portmann, R; Suter, K; Weidekamm, E, 1987
)
1.44
" There were no significant differences in Tmax (0."( Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
De Lepeleire, I; De Schepper, PJ; Tjandra-Maga, TB; Van Hecken, A; Verbesselt, R, 1988
)
0.55
" Increased elimination half-life occurred after multiple dosing of 800 mg, from 13."( Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
Bergeron, MG; LeBel, M; Panneton, AC, 1988
)
0.54
" The apparent serum elimination half-life was about 10 h, independent of the dose."( Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
Itaya, T; Kanamaru, M; Kawahara, F; Mizuno, A; Nakashima, M; Ooie, T; Saito, S; Takiguchi, A; Uchida, H; Uematsu, T, 1988
)
0.54
" The characteristics of this new trifluorinated quinolone are the long elimination half-life of approximately 10 h and the high plasma concentrations, which exceed 2 mg/l after an oral dose of 200 mg."( Single and multiple dose pharmacokinetics of fleroxacin.
Dell, D; Partos, C; Portmann, R; Weidekamm, E, 1988
)
0.53
" Pharmacokinetic analysis was done by non-compartmental methods."( Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
Metz, R; Muth, P; Naber, K; Seelmann, R; Sorgel, F, 1988
)
0.53
" There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6."( Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.
Cerruti, F; Herrmann, M; Hirschel, B; Leemann, T; Lew, DP; Portmann, R; Schrenzel, J; Weidekamm, E, 1994
)
0.56
"9% for multiple-dose administration, 10% for single-dose administration) and in the peak concentration (25."( Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses.
Bertino, JS; Nafziger, AN; Puleo, C; Stragand, L; Wong, M, 1994
)
0.52
"h/liter) and the terminal half-life of fleroxacin (11."( Influence of rifampin on fleroxacin pharmacokinetics.
Dayer, P; Leemann, T; Lew, DP; Portmann, R; Schrenzel, J; Weidekamm, E, 1993
)
0.86
" Overall, results indicated (1) no marked differences in pharmacokinetic parameters in pregnant versus nonpregnant females, (2) fleroxacin levels in embryonic tissues were similar to maternal plasma levels, and (3) there was a correlation between exposure and embryolethal doses for all fluoroquinolones which resulted in embryolethality except norfloxacin."( Developmental toxicity of fleroxacin and comparative pharmacokinetics of four fluoroquinolones in the cynomolgus macaque (Macaca fascicularis).
Hendrickx, AG; Hummler, H; Richter, WF, 1993
)
0.79
"The pharmacokinetic properties of fleroxacin in relation to other quinolones are presented."( Overview of the pharmacokinetics of fleroxacin.
Nightingale, CH, 1993
)
0.84
" As a consequence of reduced clearance, the mean elimination half-life in patients increased from 13."( Pharmacokinetics of fleroxacin in renal impairment.
Weidekamm, E, 1993
)
0.61
" Drug concentrations were determined by a reversed-phase high-pressure liquid chromatography method and were used for the pharmacokinetic evaluation."( Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women.
Dan, M; Portmann, R; Sagiv, R; Weidekamm, E; Zakut, H, 1993
)
0.64
"The pharmacokinetic profile of fleroxacin was studied in eight noninfected patients receiving regular hemodialysis (four women and four men; mean age, 63 years; age range, 48 to 73 years)."( Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.
Frey, FJ; Kinzig, M; Schaedeli, F; Sörgel, F; Uehlinger, DE, 1996
)
0.9
"A metaanalysis was conducted on data from 172 subjects (healthy volunteers and uninfected patients) included in 10 pharmacokinetic studies of fleroxacin after oral administration."( Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.
Reigner, BG; Welker, HA, 1996
)
0.75
" No difference in other pharmacokinetic parameters was noted."( Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers.
Bertino, JS; Nafziger, AN, 1996
)
0.6
" Appropriate mathematical models were applied with the aid of a microcomputer software program for the estimation of the basic pharmacokinetic parameters."( Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
Chukwuani, CM; Coker, HA; Ifudu, ND; Oduola, AM; Sowunmi, A,
)
0.38
"Previous pharmacokinetic studies have shown that a number of the quinolones inhibit the metabolism of caffeine."( Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.
Kim, MK; Nicolau, D; Nightingale, C, 2003
)
0.57
" Plasma and urine concentrations were determined by validated high-performance liquid chromatography procedures and the data were analysed by noncompartmental linear pharmacokinetic methods."( Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.
Kim, MK; Nicolau, D; Nightingale, C, 2003
)
0.57
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

Fleroxacin can be combined with other antibiotics to enlarge the spectrum of activity. We used a rat model of intra-abdominal abscesses in which the inoculum consisted of pooled rat feces mixed with BaSO4.

ExcerptReferenceRelevance
"To assess the potential efficacy of fleroxacin in combination with clindamycin or metronidazole in mixed aerobic and anaerobic infections, we used a rat model of intra-abdominal abscesses in which the inoculum consisted of pooled rat feces mixed with BaSO4."( Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.
Eliopoulos, GM; Ferraro, MJ; Holden, J; Moellering, RC; Pefanis, A; Thauvin-Eliopoulos, C, 1994
)
0.94
" Thus, fleroxacin can be combined with other antibiotics to enlarge the spectrum of activity."( In vitro activity of fleroxacin in combination with other antimicrobial agents.
Chin, NX; Neu, HC, 1993
)
1.06
"Convulsant activity of pazufloxacin mesilate (PZFX mesilate), a new quinolone antibacterial agent for intravenous use, in combination with nonsteroidal anti-inflammatory drug (NSAID) was investigated in mice after intravenous or intracerebroventricular administration."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31

Bioavailability

The relative bioavailability of fleroxacin given with sucralfate, calculated from the area under the concentration-time curve, was 76%. The absolute bioavailability (BA) was evaluated in 19 adult Nigerian male volunteers.

ExcerptReferenceRelevance
" The relative bioavailability of fleroxacin given with sucralfate, calculated from the area under the concentration-time curve, was 76% compared with that of fleroxacin alone."( Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers.
Lubowski, TJ; Nightingale, CH; Quintiliani, R; Sweeney, K, 1992
)
0.83
" These data suggest that bioavailability of the drug is unchanged."( Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Dhib, M; Fillastre, JP; Godin, M; Leroy, A; Moulin, B; Singlas, E; Sultan, E; Taburet, AM, 1990
)
0.63
" Assuming that the bioavailability (f) is complete, the apparent volume of distribution (Vd/f) was lower in elderly (0."( Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Devillers, A; Fillastre, JP; Singlas, E; Taburet, AM; Thomare, P; Veyssier, P, 1990
)
0.63
"The pharmacokinetic properties of the new fluoroquinolones are characterized by a high volume of distribution, long biological half-life, low serum protein binding, elimination by renal and extrarenal mechanisms with high total and renal clearances, limited biotransformation and moderate to excellent bioavailability after oral administration."( Quinolone pharmacokinetics and metabolism.
Boeckk, M; Borner, K; Deppermann, N; Höffken, G; Koeppe, P; Lode, H, 1990
)
0.28
" The absolute bioavailability (extent of absorption) of the tablet amounted to 96%, indicating a complete absorption of this galenic formulation."( A new trifluorinated quinolone: Ro 23-6240 (AM 833).
Dell, D; Stöckel, K; Weidekamm, E, 1987
)
0.27
" The absolute bioavailability of the administered tablet was practically 100%."( Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
Dell, D; Lücker, PW; Partos, C; Portmann, R; Suter, K; Weidekamm, E, 1987
)
0.53
" Oral clearance of fleroxacin (CL = CL/F, where F is bioavailability was slightly, but not significantly, reduced during the bacteremic phase (oral clearance, 43."( Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.
Cerruti, F; Herrmann, M; Hirschel, B; Leemann, T; Lew, DP; Portmann, R; Schrenzel, J; Weidekamm, E, 1994
)
0.89
" Although a meal high in fat and containing liquid calcium reduces the peak concentration by approximately 25%, a minimal effect on bioavailability is seen with concomitant food administration."( Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses.
Bertino, JS; Nafziger, AN; Puleo, C; Stragand, L; Wong, M, 1994
)
0.52
" Although, in patients with CF, the extent of drug absorption varies widely and the rate of absorption is slower, bioavailability is not altered."( Drug disposition in cystic fibrosis.
Pons, G; Rey, E; Tréluyer, JM, 1998
)
0.3
"The absolute bioavailability (BA) of ciprofloxacin and fleroxacin were evaluated in 19 adult Nigerian male volunteers."( Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
Chukwuani, CM; Coker, HA; Ifudu, ND; Oduola, AM; Sowunmi, A, 2000
)
0.83
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Fleroxacin, administered intravenously at a dosage of 400 mg once a day, was compared with ceftazidime, 0.5 mg. The results also confirmed earlier findings, advocating a once-daily dosage schedule for fleroxacins also in the Negroid population.

ExcerptRelevanceReference
"In a double-blind randomized trial, we evaluated the efficacy and safety of three oral dosage regimens of fleroxacin, a new fluoroquinolone, once daily in 62 patients for the treatment of complicated urinary tract infections."( Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.
Hoepelman, AI; Verhoef, J; Wolfhagen, MJ, 1990
)
0.76
" Blood samples (n = 10) and total urine output were collected during a 24-h dosing interval."( Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
Awni, W; Heim-Duthoy, K; Peltier, G, 1990
)
0.56
" These findings suggest that fleroxacin dosage may need to be reduced in patients with severe renal disease; in haemodialysed patients, treated every 2 days, a single dose of fleroxacin 400mg is recommended at the end of each dialysis session."( Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Dhib, M; Fillastre, JP; Godin, M; Leroy, A; Moulin, B; Singlas, E; Sultan, E; Taburet, AM, 1990
)
0.92
" On the basis of the findings of this single dose study, no major dosage adjustments are needed for patients of this age range except for those with creatinine clearance less than 30 ml/min."( Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Devillers, A; Fillastre, JP; Singlas, E; Taburet, AM; Thomare, P; Veyssier, P, 1990
)
0.63
" A theophylline dosage individualized to obtain a mean theophylline concentration in plasma of 10 +/- 3 micrograms/ml was administered for 1 week to each subject."( Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.
LeBel, M; Parent, M; St-Laurent, M, 1990
)
0.68
" Dosage adjustments are required, particularly in severe renal failure and for the drugs almost exclusively excreted, in unchanged form, via the renal route."( Pharmacokinetics of quinolones in renal insufficiency.
Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990
)
0.28
" Profiles of drug levels in serum were dose related over a single dose range from 2 to 40 mg/kg and not modified significantly during multiple dosing in dogs."( Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys.
Irikura, T; Ishikawa, N; Kusajima, H; Machida, M; Uchida, H, 1986
)
0.27
" Both these parameters are favourable kinetic prerequisites for a once-a-day dosage regimen."( A new trifluorinated quinolone: Ro 23-6240 (AM 833).
Dell, D; Stöckel, K; Weidekamm, E, 1987
)
0.27
" The peak levels of fleroxacin in plasma were significantly higher after multiple dosing of 800 mg (14."( Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
Bergeron, MG; LeBel, M; Panneton, AC, 1988
)
0.86
" Steady state serum concentrations were achieved from day 3 onwards by repeated doses of twice-a-day dosage regimen and were 2-4 and 5-9 mg/l after 200 and 400 mg bid, respectively."( Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
Itaya, T; Kanamaru, M; Kawahara, F; Mizuno, A; Nakashima, M; Ooie, T; Saito, S; Takiguchi, A; Uchida, H; Uematsu, T, 1988
)
0.54
"Pharmacokinetics of fleroxacin following single and multiple dosing were studied in healthy male volunteers."( Single and multiple dose pharmacokinetics of fleroxacin.
Dell, D; Partos, C; Portmann, R; Weidekamm, E, 1988
)
0.86
"From in-vitro data, recommendations for dosing with fleroxacin are presented."( Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
Bauernfeind, A; Eberlein, E; Hörl, G, 1988
)
0.79
" In Japanese studies using a lower dosage of 200 or 300 mg/day, fleroxacin was reported to be bacteriologically effective in a range of infections, including urinary tract and upper and lower respiratory tract infections."( Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
Balfour, JA; Peters, DH; Todd, PA, 1995
)
1.97
" Renal function appeared to be the key element that had to be taken into consideration to adapt fleroxacin dosage profiles in our patient population."( Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.
Cerruti, F; Herrmann, M; Hirschel, B; Leemann, T; Lew, DP; Portmann, R; Schrenzel, J; Weidekamm, E, 1994
)
0.78
" Once-daily dosing with 400 mg of intravenous fleroxacin was equivalent to a standard multidose regimen with respect to rates of bacteriologic and clinical cure in the treatment of complicated UTI."( Comparison of intravenous fleroxacin with ceftazidime for treatment of complicated urinary tract infections.
Cox, CE, 1993
)
0.84
"This study enrolled patients with complicated urinary tract infections (UTIs) in a trial to determine the efficacy and safety of sequential therapy with intravenous fleroxacin (first 3 days) followed by oral fleroxacin, for a total course of 7-14 days, both administered at a dosage of 400 mg once a day."( A sequential study of intravenous and oral fleroxacin in the treatment of complicated urinary tract infection.
Amarshi, N; Craft, RB; Gelfand, MS; Grogan, J; Simmons, BP, 1993
)
0.74
" Fleroxacin was given at a dosage of 400 mg once daily, and AMX/CP was given at a dosage of 500 mg/125 mg three times a day."( Open trial of oral fleroxacin versus amoxicillin/clavulanate in the treatment of infections of skin and soft tissue.
Powers, RD, 1993
)
1.52
" Accumulation of drug in the body is minimal, and change from intravenous to oral dosing results in nearly identical serum concentrations."( Overview of the pharmacokinetics of fleroxacin.
Nightingale, CH, 1993
)
0.56
" After administration of the standard dose of 400 mg once daily, the maximal plasma concentrations were 5-7 mg/L at steady-state and the minimal concentrations were approximately 1 mg/L at the end of the dosing interval."( Penetration of fleroxacin into body tissues and fluids.
Portmann, R; Weidekamm, E, 1993
)
0.64
" Since adverse events appear to occur in women more commonly than in men, dose-response studies of fleroxacin in women may be appropriate."( Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers.
Bertino, JS; Nafziger, AN, 1996
)
0.81
" The once daily dosage of fleroxacin [400 mg once daily intravenously (i."( Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia.
Marklein, G, 1996
)
0.59
" Clinafloxacin at higher dosage (45 mg/kg/d) resulted in a decrease in myeloid progenitors in BM."( Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones.
Fabian, I; Gruss, T; Kletter, Y; Shalit, I; Weiss, K, 1997
)
0.3
" This novel information may be useful for the rational development of dosage schedules and may improve predictions regarding therapeutic outcome."( Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans.
Agneter, E; Burgdorff, T; Eichler, HG; Georgopoulos, A; Haag, O; Jansen, B; Müller, M; Pehamberger, H; Stanek, G; Weninger, W, 1996
)
0.29
"The results suggest that both fleroxacin and ciprofloxacin are safe and effective for the treatment of complicated urinary tract infections at the higher doses used in phase 2, with fleroxacin offering the advantage of a once-daily dosing regimen."( Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections.
Bischoff, W; Frankenschmidt, A; Kullmann, K; Naber, KG, 1997
)
0.98
"5 and 6 h after dosing and the drug was still detectable in plasma 48 h after dosing (0."( Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics.
Förster, C; Günther, T; Lozo, E; Merker, HJ; Schwabe, R; Stahlmann, R; Vormann, J; Zippel, U, 1997
)
0.3
" Both fleroxacin and lomefloxacin were given orally, the dosage was 200 mg every 12 hours or 400 mg every 24 hours for 7-14 days."( [A clinical study in the treatment of acute bacterial infections with fleroxacin].
Cui, H; Hou, J; Li, J, 1996
)
1.01
" The results also confirmed earlier findings, advocating a once-daily dosage schedule for fleroxacin also in the Negroid population."( Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
Chukwuani, CM; Coker, HA; Ifudu, ND; Oduola, AM; Sowunmi, A,
)
0.6
" The appropriate dosage of quinolones has not been definitively established."( Drug disposition in cystic fibrosis.
Pons, G; Rey, E; Tréluyer, JM, 1998
)
0.3
" In addition, concurrent dosing of BPAA (1 microgram/body) did not reduce the convulsion-inducing dose of PZFX mesilate."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31
"HPLC determination of fleroxacin in dosage forms was carried out using either reversed-phase column YMC pack ODS-AQ or Supelco LC Hisep shielded hydrophobic phase column, with UV detection at 280 nm."( Validation of an HPLC method for the determination of fleroxacin and its photo-degradation products in pharmaceutical forms.
Djurdjevic, P; Jelikic-Stankov, M; Laban, A,
)
0.69
" Its dosage must be adjusted according to the degree of renal insufficiency."( Capillary electrophoresis with electrochemiluminescence detection for simultaneous determination of proline and fleroxacin in human urine.
Li, L; Sun, H; Wu, Y, 2009
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
topoisomerase IV inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase IV, which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
antibacterial drugA drug used to treat or prevent bacterial infections.
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
fluoroquinolone antibioticAn organonitrogen heterocyclic antibiotic containing a quinolone (or quinolone-like) moiety and which have a fluorine atom attached to the central ring system.
difluorobenzeneAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying two fluorine atoms.
N-alkylpiperazine
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency3.16230.177814.390939.8107AID2147
GLI family zinc finger 3Homo sapiens (human)Potency29.84930.000714.592883.7951AID1259369
estrogen nuclear receptor alphaHomo sapiens (human)Potency14.96010.000229.305416,493.5996AID743079
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.70790.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (228)

Assay IDTitleYearJournalArticle
AID203135In vitro antibacterial activity against Serratia marcescens SM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID64899In vitro for antibacterial activity against Escherichia coli 1527E (Ec(C))1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID42680In vitro antibacterial activity against Clostridium difficile 6511992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID1427883Antibacterial activity against Enterobacter aerogenes EA298 over-expressing TolC after 18 hrs by broth dilution method2017European journal of medicinal chemistry, Feb-15, Volume: 127New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.
AID205543Minimum inhibitory concentration against Staphylococcus aureus (UC76).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID748609Antibacterial activity against tolC-deficient Enterobacter aerogenes EA298 assessed as growth inhibition after 18 hrs by two-fold serial dilution method2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
New Peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging.
AID244848In vitro minimum inhibitory concentration against Staphylococcus aureus Smith2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID244879In vitro minimum inhibitory concentration against Streptococcus pneumoniae type III2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID203141In vitro antibacterial activity was determined against Serratia marcescens 10711990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID38484In vitro antibacterial activity against Bacteroides fragilis F117A1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID40339Compound was tested in vitro for its antibacterial activity (minimum inhibitory concentration) against Bacteroides fragilis A 22862.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID748611Antibacterial activity against acrAB-deficient Escherichia coli AG100A assessed as growth inhibition after 18 hrs by two-fold serial dilution method2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
New Peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging.
AID163943In vitro antibacterial activity against Pseudomonas aeruginosa 87801992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID64898In vitro for antibacterial activity against Escherichia coli 1346 (Ec(A))1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID201413In vitro antibacterial activity against staphylococcus aureus smith1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID70760In vitro antibacterial activity against Escherichia coli 2571991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID65038In vitro for antibacterial activity against Escherichia coli B (Ec(B))1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID78687Lowest concentration necessary to induce DNA gyrase-mediated cleavage of DNA1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID52946In vitro antibacterial activity was determined against Citrobacter freundii BS-161990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID66227In vitro for antibacterial activity against Enterobacter cloacae P991992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID208310Minimum inhibitory concentration against Streptococcus pneumoniae (SV-1).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID65224In vitro antibacterial activity against Escherichia coli TEM-1 (constitutive beta-lactamase producer)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID140680Compound was evaluated in vivo in urine sample collected over 24 hours for its concentration after 40 mg/kg peroral administration to mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID210022Antibacterial activity against Streptococcus pneumoniae (SV-1)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID164733Compound was tested in vitro for its antibacterial activity (minimum inhibitory concentration, MIC) against Pseudomonas aeruginosa A 98431991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID152305In vitro antibacterial activity against Proteus mirabilis 901992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID163780In vitro antibacterial activity was determined against Pseudomonas aeruginosa ATCC 278531990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1427880Antibacterial activity against wild type Escherichia coli AG100 after 18 hrs by broth dilution method2017European journal of medicinal chemistry, Feb-15, Volume: 127New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.
AID64900In vitro antibacterial activity against Escherichia coli 259221992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID13688Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID52927In vivo activity in murine against Citrobacter freundii BS#16 infection after sc administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID163568In vitro antibacterial activity against proteus vulgaris ATCC 6380 (constitutive beta-lactamase producer)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID209611In vitro antibacterial activity was determined against Streptococcus pyogenes 41990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID68822In vivo activity in murine against Escherichia coli 257 infection after sc administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID209763Minimum inhibitory concentration against Streptococcus pyogenes (C203).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID95878In vitro for antibacterial activity against Klebsiella oxytoca 1082E1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID209864In vivo activity in murine against Streptococcus pneumoniae 6301 infection after sc administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID162744In vitro antibacterial activity (minimum inhibitory concentration, MIC) against Proteus mirabilis A 99001991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID24517Compound was evaluated in vivo in blood samples from the orbital sinus for its half life after 40 mg/kg of intramuscular administration in mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID150911In vitro antibacterial activity against Ps. aeruginosa 18SH (constitutive beta-lactamase producer)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID68668In vitro antibacterial activity was determined against Escherichia coli TEM-1 (TEM-1 (class IIIa) beta-lactamase producer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID96244In vitro antibacterial activity against Klebsiella pneumoniae A1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID95902In vivo activity in murine against Klebsiella pneumoniae A infection after sc administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID210205In vitro antibacterial activity against Streptococcus pneumoniae 63011991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID40940In vitro for antibacterial activity against Bacillus subtilis ATCC 5853691992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID244860In vitro minimum inhibitory concentration against Pseudomonas aeruginosa IID12102005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin.
AID205830In vitro antibacterial activity against Staphylococcus aureus A 242271991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID210201In vitro antibacterial activity against Streptococcus pneumoniae A 95851991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID164081In vivo activity in murine against Pseudomonas aeruginosa 5712 infection after sc administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID78707MIC at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 ug/mL by using Gyrase Induced DNA-Cleavage assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID69470Minimum inhibitory concentration against Escherichia coli (vogel)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID67999In vivo activity in murine against Enterobacter cloacae 5699 infection after sc administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID205831In vitro antibacterial activity (minimum inhibitory concentration, MIC) against Staphylococcus aureus A 9537.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID50857In vitro antibacterial activity against clostridium histolyticum 503-861992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID162756In vitro antibacterial activity was determined against Proteus mirabilis 901990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID207175Antibacterial activity against Staphylococcus aureus (H228)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID68666In vitro antibacterial activity was determined against Escherichia coli ATCC 259221990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID95533In vitro antibacterial activity against Klebsiella pneumoniae A 96641991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID163252In vitro antibacterial activity was determined against Proteus vulgaris 1028 BC (Class Ic beta-lactamase overproducer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID93887Minimum inhibitory concentration against Klebsiella pneumoniae (MGH-2)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID11144Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID208788In vitro antibacterial activity against streptococcus pneumoniae 63011992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID163100Minimum inhibitory concentration against Pseudomonas aeruginosa. (UI-18)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID78688Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID70591In vitro antibacterial activity against Escherichia coli A 151191991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID206552In vivo activity in murine against Staphylococcus aureus 753(MR) infection after sc administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID68667In vitro antibacterial activity was determined against Escherichia coli DC-O1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID68506Minimum inhibitory concentration against Enterobacter cloacae. (MA2446).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID65225In vitro antibacterial activity against Escherichia coli UB1005 (nalidixic acid-resistant strain)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID11143Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID206759In vitro antibacterial activity was determined against Staphylococcus aureus ATCC 29213 (inducible, low level beta-lactamase producer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID78550Concentration required for 50% inhibition of gyrase.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID69784Antibacterial activity against Escherichia coli (vogel)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID69782Antibacterial activity against Escherichia coli (H560)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1427881Antibacterial activity against AcrAB deficient Escherichia coli AG100A after 18 hrs by broth dilution method2017European journal of medicinal chemistry, Feb-15, Volume: 127New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.
AID201252In vitro antibacterial activity against Staphylococcus aureus 67(methicillin resistant)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID206757In vitro antibacterial activity was determined against Staphylococcus aureus 95 (Methicillin-resistant, high-level beta-lactamase producer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID24518Compound was evaluated in vivo in blood samples from the orbital sinus for its half life after 40 mg/kg of peroral administration in mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID67402In vitro antibacterial activity was determined against Enterococcus faecalis ATCC 292121990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID205531Minimum inhibitory concentration against Staphylococcus aureus (H-228).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID206118In vitro antibacterial activity against Staphylococcus aureus Smith(MS)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID206553In vivo activity in murine against Staphylococcus aureus Smith (MS) infection after sc administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID163052Minimum inhibitory concentration against Providencia rettgeri. (M1771)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID69469Minimum inhibitory concentration against Escherichia coli (H560)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID209454In vitro antibacterial activity against Streptococcus pyogenes 41991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID42681In vitro antibacterial activity against Clostridium difficile 7011992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID206506In vitro for antibacterial activity against Staphylococcus haemolyticus 75 (quinolone-resistant)1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID95885Antibacterial activity against Klebsiella pneumonia (MGH-2)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID65043Effect on replication DNA biosynthesis in Escherichia coli H560 (permeabilised cells).1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID64080In vitro antibacterial activity against Escherichia coli 2571992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID206117In vitro antibacterial activity against Staphylococcus aureus 95(MR)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID38472In vitro antibacterial activity against Bacteroides thetaiotaomicron 62B1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID203321In vitro antibacterial activity against serratia marcescens SM (constitutive beta-lactamase producer)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID244844In vitro minimum inhibitory concentration against Escherichia coli NIHJ JC-22005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin.
AID163937In vitro for antibacterial activity against Pseudomonas aeruginosa 799/611992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID41400In vitro antibacterial activity against bacteroides fragilis S21992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID208120In vitro antibacterial activity was determined against Streptococcus pneumoniae 63011990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID205394In vitro antibacterial activity (minimum inhibitory concentration) against Serratia marcescens A 20019.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID66230In vitro antibacterial activity against enterobacter cloacae P99 (constitutive beta-lactamase producer)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID209116In vivo effective dose against mice infected with streptococcus pyogenes 41990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID125256In vitro antibacterial activity against Morganella morganii A 151531991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID66246In vitro antibacterial activity was determined against Enterobacter cloacae P99 (Class Ia beta-lactamase overproducer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID222085Minimum inhibitory concentration against gram-negative enterobacteriaceae.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID52941In vitro antibacterial activity against Citrobacter freundii BS 161991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID68185In vitro antibacterial activity against Enterobacter cloacae P991991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID123084In vitro for antibacterial activity against Micrococcus luteus ATCC 83401992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID206755In vitro antibacterial activity was determined against Staphylococcus aureus 1059B ( inducible, high level beta-lactamase producer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1427882Antibacterial activity against multidrug resistant Enterobacter aerogenes EA289 over-expressing AcrAB-TolC after 18 hrs by broth dilution method2017European journal of medicinal chemistry, Feb-15, Volume: 127New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.
AID209100In vivo activity in murine against Streptococcus pyogenes 4 infection after sc administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID74727Antibacterial activity against five Gram-negative bacteria1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID205371In vivo activity in murine against Serratia marcescens SM infection after sc administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID748610Antibacterial activity against multidrug-resistant Enterobacter aerogenes EA289 overexpressing AcrAB-tolC assessed as growth inhibition after 18 hrs by two-fold serial dilution method2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
New Peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging.
AID13689Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID202125In vitro antibacterial activity against Streptococcus pyogenes 41992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID748612Antibacterial activity against wild type Escherichia coli AG100 assessed as growth inhibition after 18 hrs by two-fold serial dilution method2013ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6
New Peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging.
AID85970In vitro antibacterial activity against Haemophilus influenzae A 215151991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID94224In vitro antibacterial activity against klebsiella pneumoniae A1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID209248Minimum inhibitory concentration against Streptococcus faecalis (MGH-2).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID164887In vitro antibacterial activity against Pseudomonas aeruginosa 57121991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID165204In vitro antibacterial activity was determined against Pseudomonas aeruginosa 18S/H (Class Id beta-lactamase overproducer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID68823In vivo effective dose against mice infected with Escherichia coli 2571990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID68184In vitro antibacterial activity against Enterobacter cloacae 56991991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID123058In vitro antibacterial activity was determined against Micrococcus luteus PCI1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID241266Inhibitory concentration against DNA gyrase of Staphylococcus aureus2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin.
AID42688In vitro antibacterial activity against Clostridium perfringens 134241992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID74853Antibacterial activity against five Gram-positive bacteria targeting topoisomerase II (DNA gyrase B GyrB)1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID207405In vitro for antibacterial activity against Staphylococcus aureus 8871992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID208022In vitro antibacterial activity was determined against Streptococcus pneumoniae 63011990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID78708Inhibitory activity against Escherichia coli DNA gyrase (represented as MNEC)1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
AID50552In vitro antibacterial activity against citrobacter freundii BS-16 (constitutive beta-lactamase producer)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID51918Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID201254In vitro antibacterial activity against Staphylococcus aureus 753 (constitutive beta-lactamase producer)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Dual-action penems and carbapenems.
AID140679Compound was evaluated in vivo in urine sample collected over 24 hours for its concentration after 40 mg/kg intramuscular administration to mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID68180In vitro antibacterial activity against Enterobacter cloacae A 96561991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID164385Antibacterial activity against Pseudomonas aeruginosa (UI-18)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID67228In vitro antibacterial activity against Enterococcus faecalis A 98091991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (415)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990110 (26.51)18.7374
1990's224 (53.98)18.2507
2000's39 (9.40)29.6817
2010's30 (7.23)24.3611
2020's12 (2.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.78 (24.57)
Research Supply Index6.24 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index44.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials67 (14.99%)5.53%
Reviews15 (3.36%)6.00%
Case Studies7 (1.57%)4.05%
Observational0 (0.00%)0.25%
Other358 (80.09%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]